keyword
MENU ▼
Read by QxMD icon Read
search

biliary tract cancer

keyword
https://www.readbyqxmd.com/read/29238914/clinical-and-genetic-implications-of-dna-mismatch-repair-deficiency-in-biliary-tract-cancers-associated-with-lynch-syndrome
#1
Jordan M Cloyd, Yun Shin Chun, Naruhiko Ikoma, Jean Nicolas Vauthey, Tlhomas A Aloia, Amanda Cuddy, Miguel A Rodriguez-Bigas, Y Nancy You
PURPOSE: Patients with Lynch syndrome (LS) have a significantly elevated lifetime risk of developing biliary tract cancers (BTCs) compared to the general population. However, few studies have characterized the clinical characteristics, genetic features, or long-term outcomes of mismatch-repair deficient (dMMR) cholangiocarcinomas associated with LS. METHODS: A retrospective review of a prospectively maintained Familial High-Risk GI Cancer Clinic database identified all patients with BTCs evaluated from 2006 to 2016 who carried germline mutations in MLH1, MSH2, MSH6, or PMS2...
December 14, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29234186/primary-leiomyosarcoma-of-the-mesentery-a-case-report
#2
Varsha Dalal, Manveen Kaur, Reetika Menia, Fouzia Siraj, Amar Bhatnagar, Usha Agrawal
Mesenteric masses are infrequent lesions ranging from benign cysts to aggressive malignancies and often present a diagnostic and therapeutic challenge. The mesentery is a frequent recipient of metastases from the gastrointestinal tract, pancreas, and biliary cancers. Primary mesenteric tumors are relatively rare, mostly mesenchymal in origin and benign in nature. Examples include gastrointestinal stromal tumors and smooth muscle tumors. We describe a 50-year-old woman, who presented with a lump in the left hypochondrium along with altered bowel habits of 2 years' duration...
September 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29224898/clinical-outcome-of-patients-with-advanced-biliary-tract-cancer-in-a-dedicated-phase-i-unit
#3
R Sundar, A Custodio, A Petruckevich, M Chénard-Poirier, M Ameratunga, D Collins, J Lim, S B Kaye, N Tunariu, U Banerji, J de Bono, J Lopez
AIMS: Advanced biliary tract carcinomas (ABC) are malignancies with limited effective therapies for advanced disease. There is little published evidence of outcomes of ABC patients participating in phase I clinical trials. MATERIALS AND METHODS: Patient characteristics, treatment details and outcomes of ABC patients treated at a dedicated phase I unit were captured and analysed from case and trial records. RESULTS: In total, 123 ABC patients were included in the study, of which 48 patients participated in 41 different phase I trials; 75 (61%) did not participate due to rapid disease progression or patient choice...
December 7, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29222963/preoperative-biliary-drainage-adversely-affects-surgical-outcomes-in-periampullary-cancer-a-retrospective-and-propensity-score-matched-analysis
#4
Hongeun Lee, Youngmin Han, Jae Ri Kim, Wooil Kwon, Sun-Whe Kim, Jin-Young Jang
BACKGROUND/PURPOSE: The use of PBD for managing patients with periampullary cancer awaiting surgery remains controversial. The impact of PBD status and type on surgical outcomes has not been established, leading to a lack of consensus. We aimed to evaluate the impact of preoperative biliary drainage (PBD) on short-term surgical outcomes in curatively resected periampullary cancer. METHODS: We retrospectively reviewed data from patients undergoing curative periampullary cancer resection...
December 9, 2017: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/29207941/uneven-acute-non-alcoholic-fatty-change-of-the-liver-after-percutaneous-transhepatic-portal-vein-embolization-in-a-patient-with-hilar-cholangiocarcinoma-a-case-report
#5
Chun-Yi Tsai, Motoi Nojiri, Yukihiro Yokoyama, Tomoki Ebata, Takashi Mizuno, Masato Nagino
BACKGROUND: Portal vein embolization is essential for patients with biliary cancer who undergo extended hepatectomy to induce hypertrophy of the future remnant liver. Over 830 patients have undergone the portal vein embolization at our institution since 1990. Non-alcoholic fatty liver disease is an entity of hepatic disease characterized by fat deposition in hepatocytes. It has a higher prevalence among persons with morbid obesity, type 2 diabetes, and hyperlipidemia. Neither the mechanism of hepatic hypertrophy after portal vein embolization nor the pathophysiology of non-alcoholic fatty liver disease has been fully elucidated...
December 6, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/29199665/metastasectomy-for-recurrent-or-metastatic-biliary-tract-cancers-a-single-center-experience
#6
I Park, Y S Kim, S J Sym, H K Ahn, K K Kim, Y H Park, J N Lee, D B Shin
PURPOSE: To assess efficacy or long-term result of metastasectomy for recurrent or metastatic biliary tract carcinoma (BTC), we conducted a retrospective review of the outcomes of metastasectomy for recurrent or metastatic BTCs, comprising intrahepatic cholangiocellular carcinoma (IHCCC), proximal and distal common bile duct cancer (pCBDC and dCBDC), gallbladder cancer (GBC), and ampulla of Vater cancer (AoVC). PATIENTS AND METHODS: The clinicopathological features and outcomes of BTC patients who underwent surgical resection for the primary and metastatic disease at the Gachon University Gil Medical Centre from 2003 to 2013 were reviewed retrospectively...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29174787/updated-trends-in-gallbladder-and-other-biliary-tract-cancers-worldwide
#7
EDITORIAL
Tomonori Matsumoto, Hiroshi Seno
No abstract text is available yet for this article.
November 22, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29164423/successful-radical-surgical-resection-of-initially-unresectable-intrahepatic-cholangiocarcinoma-by-downsizing-chemotherapy-with-gemcitabine-plus-cisplatin-a-case-report
#8
Ryosuke Takayanagi, Shigetsugu Takano, Kensuke Sugiura, Hideyuki Yoshitomi, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Atsushi Kato, Masaru Miyazaki, Masayuki Ohtsuka
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a subtype of biliary tract cancer (BTC). Recently, downsizing chemotherapy has been applied to initially unresectable BTCs, including ICC. CASE PRESENTATION: We report a case of liver resection in a 23-year-old woman who was diagnosed with initially unresectable ICC attached to the inferior vena cava, with portal vein (PV) cavernous transformation. Positron emission tomography (PET) showed fluorodeoxyglucose (FDG) uptake in the para-aortic lymph nodes...
November 21, 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/29163784/imp2-igf2bp2-expression-but-not-imp1-and-imp3-predicts-poor-outcome-in-patients-and-high-tumor-growth-rate-in-xenograft-models-of-gallbladder-cancer
#9
Sonja M Kessler, Eva Lederer, Stephan Laggai, Nicole Golob-Schwarzl, Kevan Hosseini, Johannes Petzold, Caroline Schweiger, Robert Reihs, Marlen Keil, Jens Hoffmann, Christian Mayr, Tobias Kiesslich, Martin Pichler, Kyung Sik Kim, Hyungjin Rhee, Young Nyun Park, Sigurd Lax, Peter Obrist, Alexandra K Kiemer, Johannes Haybaeck
Overexpression of the oncofetal insulin-like growth factor 2 mRNA-binding protein 2 (IMP2/IGF2BP2) has been described in different cancer types. Gallbladder carcinoma (GBC) is a rare but highly aggressive cancer entity with late clinical detection and poor prognosis. The aim of this study was to investigate the role of IMP2 in human GBC. Tissue microarrays (TMAs) of an international multi-center GBC sample collection from n = 483 patients were analyzed by immunohistochemistry. IMP2 immunoreactivity was found in 74...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29149490/multilevel-heterogeneity-of-biliary-tract-cancers-may-affect-the-modelling-of-prognosis
#10
EDITORIAL
Vincenzo Cardinale, Guido Carpino
No abstract text is available yet for this article.
December 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29148857/update-on-the-role-and-therapeutic-potential-of-polycomb-repressive-complexes-in-biliary-tract-cancer
#11
Daniel Neureiter, Tobias Kiesslich, Markus Ritter, Christian Mayr
No abstract text is available yet for this article.
November 17, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/29145038/precision-medicine-for-patients-with-advanced-biliary-tract-cancers-an-effective-strategy-within-the-prospective-moscato-01-trial
#12
Loic Verlingue, David Malka, Adrien Allorant, Christophe Massard, Charles Ferté, Ludovic Lacroix, Etienne Rouleau, Nathalie Auger, Maud Ngo, Claudio Nicotra, Thierry De Baere, Lambros Tselikas, Bakar Ba, Stefan Michiels, Jean-Yves Scoazec, Valérie Boige, Michel Ducreux, Jean-Charles Soria, Antoine Hollebecque
BACKGROUND: Recommended treatments of patients with advanced biliary tract cancer (aBTC) are limited to one chemotherapy doublet. Nevertheless, efficacy of treatment personalisation for aBTCs is supported by accumulating evidences but remains to be evaluated. PATIENTS AND METHODS: Patients with aBTCs included in the prospective clinical trial MOSCATO-01 were treated by at least one previous systemic treatment, had an ECOG performance status of 0-1, and at least one tumour site accessible to biopsy...
November 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29142904/kras-g12d-upregulates-notch-signaling-to-induce-gallbladder-tumorigenesis-in-mice
#13
Wen-Cheng Chung, Junqing Wang, Yunyun Zhou, Keli Xu
Background: Kras mutations and increased Notch activation occur frequently in gallbladder cancer. However, their roles in gallbladder carcinogenesis have not been defined. This study was aimed at determining whether expression of mutant Kras was sufficient to induce gallbladder carcinoma and whether Notch deregulation played a role in this context. Methods: We determined Cre recombination activity of Pdx1-Cre in the gallbladder using a reporter strain and examined gallbladder tumor development in the Kras(LSL- G12D/+);Pdx1-Cre mice...
September 2017: Oncoscience
https://www.readbyqxmd.com/read/29138340/phase-i-study-of-chimeric-antigen-receptor-modified-t-cells-in-patients-with-egfr-positive-advanced-biliary-tract-cancers
#14
Yelei Guo, Kai-Chao Feng, Yang Liu, Zhiqiang Wu, Hanren Dai, Qing-Ming Yang, Yao Wang, Hejin Jia, Weidong Han
PURPOSE: This study is an expanded and parallel clinical trial of epidermal growth factor receptor (EGFR)-specific chimeric antigen receptor-engineered autologous T (CART) cell immunotherapy (NCT01869166) to assess the safety and activity of CART-EGFR cell therapy in EGFR-positive advanced unresectable, relapsed/metastatic biliary tract cancers (BTCs). PATIENTS AND METHODS: Patients with EGFR-positive (>50%) advanced unresectable, relapsed/metastatic BTCs were enrolled...
November 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29133140/the-histone-methyltransferase-g9a-a-new-therapeutic-target-in-biliary-tract-cancer
#15
Christian Mayr, Katharina Helm, Martin Jakab, Markus Ritter, Rajeev Shrestha, Ramesh Makaju, Andrej Wagner, Martin Pichler, Marlena Beyreis, Stefan Staettner, Tarkan Jaeger, Eckhard Klieser, Tobias Kiesslich, Daniel Neureiter
The histone methyltransferase G9a (EHMT2) is a key enzyme for dimethylation of lysine 9 at histone 3 (H3K9me2), a suppressive epigenetic mark. G9a is over-expressed in tumour cells and contributes to cancer aggressiveness. Biliary tract cancer (BTC) is a rare cancer with dismal prognosis due to a lack of effective therapies. Currently, there are no data on the role of G9a in BTC carcinogenesis. We analysed G9a expression in n=68 BTC patient specimens and correlated the data with clinico-pathological and survival data...
November 10, 2017: Human Pathology
https://www.readbyqxmd.com/read/29121415/efficacy-and-safety-of-trametinib-in-japanese-patients-with-advanced-biliary-tract-cancers-refractory-to-gemcitabine
#16
Masafumi Ikeda, Tatsuya Ioka, Akira Fukutomi, Chigusa Morizane, Akiyoshi Kasuga, Hideaki Takahashi, Akiko Todaka, Takuji Okusaka, Caretha L Creasy, Shelby Gorman, Daniel J Felitsky, Mikiro Kobayashi, Fanghong Zhang, Junji Furuse
Gemcitabine-based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second-line treatment(s) established yet. Aberrant activation of MAPK pathway in patients with BTC indicates its importance in BTC. Trametinib is a potent, highly selective, allosteric non-competitive inhibitor of MEK1/MEK2. In this Phase IIa open-label, single-arm study, we investigated efficacy and safety of trametinib in Japanese patients with advanced BTC refractory to gemcitabine-based therapy...
November 9, 2017: Cancer Science
https://www.readbyqxmd.com/read/29115033/molecular-targets-for-the-therapy-of-cancer-associated-with-metabolic-syndrome-transcription-and-growth-factors
#17
REVIEW
Natalia V Yunusova, Irina V Kondakova, Larisa A Kolomiets, Sergey G Afanas'ev, Alena L Chernyshova, Igor V Kudryavtsev, Anastasia A Tsydenova
Metabolic syndrome (MS) is one of the leading risk factors for the development of cardiovascular diseases, type II diabetes mellitus and reproductive system diseases. Currently, not only cardiovascular disease and reproductive history risks related with MS are frequently discussed, but it has been also shown that MS is associated with increased risk of some common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer, biliary tract cancers and liver cancer for men). Further studies are required to understand the mechanisms of the involvement of MS components in the pathogenesis of malignant neoplasms...
November 8, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29114851/biweekly-cisplatin-and-gemcitabine-in-patients-advanced-biliary-tract-cancer
#18
Daniel H Ahn, Josh Reardon, Chul W Ahn, Manojkumar Bupathi, Sameh Mikhail, Christina Sing-Ying Wu, Tanios Bekaii-Saab
Treatment with cisplatin with gemcitabine (CG) demonstrates a survival benefit in patients with advanced biliary tract cancer (ABTC). However, the weekly administration can add significant toxicities that may prohibit prolonged treatment. Based on previous studies, we implemented a modified biweekly regimen of GC in an attempt to optimize the prescribed regimen with an improved toxicity profile, added convenience to patients while maintaining efficacy. Patients with ABTC were treated with fixed dose rate (FDR) gemcitabine (1000mg/m(2) /min) and cisplatin 20mg/m(2) on days 1 and 15 of every 28-day cycle...
November 7, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29113399/dck-expression-a-potential-predictive-biomarker-in-the-adjuvant-gemcitabine-chemotherapy-for-biliary-tract-cancer-after-surgical-resection-results-from-a-phase-ii-study
#19
Sang Myung Woo, Kyong-Ah Yoon, Eun Kyung Hong, Weon Seo Park, Sung-Sik Han, Sang-Jae Park, Jungnam Joo, Eun Young Park, Ju Hee Lee, Yun-Hee Kim, Tae Hyun Kim, Woo Jin Lee
The role of adjuvant therapy following resection of biliary tract cancer (BTC) remains unclear. We therefore evaluated the feasibility and toxicity of adjuvant gemcitabine in patients with BTC. This clinical phase II trial was an open-label, single center, single-arm study. Within 8 weeks after gross complete resection of BTC, patients were started on intravenous infusions of gemcitabine 1000 mg/m2 over 30 min on days 1, 8, and 15 of every 28-day cycle. Intratumoral expression of cytidine deaminase (CDA), human equilibrative transporter-1 (hENT1), deoxycytidine kinase (dCK) and ribonucleotide reductase subunit 1 (RRM1) was measured by immunohistochemistry...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29109099/targeted-gene-sequencing-of-gallbladder-carcinoma-identifies-high-impact-somatic-and-rare-germline-mutations
#20
REVIEW
Saurabh Yadav, Navonil DE Sarkar, Niraj Kumari, Narendra Krishnani, Ashok Kumar, Balraj Mittal
BACKGROUND: Gallbladder carcinoma (GBC) is a subtype of biliary tract malignancy with poor prognosis and high fatality rate. The present study was designed to uncover somatic and rare germline mutations in GBC to reveal the disease biology and understand the clinical importance of mutation profile in terms of prognostics and actionability. MATERIALS AND METHODS: We performed ultra-deep sequencing across 409 cancer-related genes in 11 GBC patients of North-Indian descent...
November 2017: Cancer Genomics & Proteomics
keyword
keyword
85541
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"